Last updated: February 11, 2026
Gilead Sciences, Inc. v. Macleods Pharmaceuticals, Ltd., 1:17-cv-01039, involves patent litigation over hepatitis C drugs. The case was filed in the District of Delaware. Gilead alleges that Macleods infringed on patents related to proprietary formulations of sofosbuvir, a key antiviral used in Gilead's hepatitis C therapy.
Litigation Timeline and Status
- Filed: March 2017
- Key allegations: Patent infringement of U.S. Patent Nos. 9,055,796 and 9,055,797 related to the use and formulation of sofosbuvir.
- Court proceedings: The case involved claim construction hearings, expert depositions, and summary judgment motions.
- Recent activity: As of the last update in 2022, the case remains unresolved, with ongoing procedural motions and potential settlement negotiations.
Core Patent Claims
Gilead holds patents covering:
- The specific crystalline form of sofosbuvir.
- The methods of synthesizing the compound.
- The methods of formulation to enhance stability and bioavailability.
Macleods seeks to produce a generic version of sofosbuvir, claiming non-infringement or invalidity of Gilead's patents. The dispute centers on the patent scope, especially concerning the crystalline form and synthesis methods.
Legal Arguments
Gilead's Position:
- The patents cover the specific crystalline form used in commercial formulations.
- Macleods' generic product infringes on the claims related to the crystalline form and synthesis process.
- The patents are valid, novel, and non-obvious.
Macleods' Defense:
- The patents are invalid due to prior art disclosure of similar crystalline forms and synthesis techniques.
- The product does not infringe because it employs different polymorphic forms or synthesis pathways.
- Patent claims are overly broad, encompassing prior art.
Key Legal Issues
- Patent validity—particularly focus on obviousness and novelty in light of prior art.
- Patent infringement—whether Macleods' formulations and processes fall within patent claims.
- Claim construction—interpretation of terms like "crystalline form" and "synthesis method."
Potential Outcomes and Impact
- If Gilead prevails, Macleods' generic is barred from entry until patent expiration in 2030.
- A ruling favoring Macleods could open the market for generics, affecting Gilead's market share and pricing.
- The case illustrates ongoing patent battles in hepatitis C therapeutics, reflecting broader industry trends.
Additional Context
- Gilead's patents have faced challenges internationally, with some jurisdictions invalidating certain claims.
- The U.S. Patent and Trademark Office (USPTO) has undergone patent examination updates, influencing current litigation strategies.
- The case is part of Gilead's broader efforts to defend its market exclusivity amid increasing generic competition.
Citations and Source Data
- Court docket, District of Delaware, Case No. 1:17-cv-01039.
- Gilead press releases and patent filings from 2016–2017.
- Patent documents: U.S. Patent Nos. 9,055,796 and 9,055,797.
- Industry analyses of hepatitis C drug patent disputes (e.g., EvaluatePharma, 2022).
- Federal Circuit case law on patent obviousness and patent claim scope.
Key Takeaways
- The case highlights the importance of polymorphic forms and synthesis methods in patent claims related to pharmaceuticals.
- Patent validity hinges on the novelty and non-obviousness of the crystalline forms and process patents.
- Market access for generics in hepatitis C treatments remains contested, with patent litigation playing a major role.
- The resolution could influence patent strategies for future antiviral drugs.
- Ongoing legal disputes reflect the balancing act between protecting innovation and enabling market competition.
FAQs
1. What are the core patents involved in this case?
The patents relate to the crystalline form of sofosbuvir and the synthesis process used to produce it.
2. Why is the crystalline form important in patent disputes?
Different crystalline forms can have varied stability and bioavailability, which are patentable attributes that protect specific formulations.
3. What defenses has Macleods used against Gilead's patents?
Macleods claims prior art invalidates the patents, and their product employs different crystalline forms or synthesis methods.
4. How does this case affect the hepatitis C drug market?
A ruling favoring Gilead keeps generic versions off the market, sustaining higher prices; a ruling favoring Macleods could accelerate generic entry.
5. When might the case be resolved?
Given the procedural history, a resolution could occur within the next 1–2 years through court decision or settlement.
Citations
[1] Court docket, District of Delaware.
[2] Gilead Sciences, Inc. 2016–2017 Press Releases.
[3] U.S. Patent Nos. 9,055,796 and 9,055,797.
[4] EvaluatePharma, 2022.
[5] Federal Circuit jurisprudence on patent obviousness.
